

-
- 607 Paper alert**
Barbara Demeneix, Susmita Hunt, Rosanne Orr & Martin Read
- 614 Patent alert**
Debabrata Banerjee, B Rajendra Krishnan & Scott J Tebbutt
- 621 Web alert**
Deborah O'Neil & Daniel Jones
- 691 Ion Niculescu-Duvaz**
Technology evaluation: Gemtuzumab ozogamicin, Celltech Group
- 697 Muhammad Mukhtar, Zahida Parveen & Roger J Pomerantz**
Technology evaluation: PRO-542, Progenics Pharmaceuticals Inc
- 703 Christian Doehn & Dieter Jocham**
Technology evaluation: CN-706, Calydon Inc

Genomics and proteomics

Edited by Lex M Cowser & Lukas A Huber

- 623 Lex M Cowser & Lukas A Huber**
Editorial overview: Genomes and proteomics
- 624 Prabhavathi B Fernandes**
The ATCG of drug discovery
- 633 Fritz Rudert**
Genomics and proteomics tools for the clinic
- 643 Eric T Fung, George L Wright Jr & Enrique A Dalmasso**
Proteomic strategies for biomarker identification: Progress and challenges
- 651 Seth Michelson & Keith Joho**
Drug discovery, drug development and the emerging world of pharmacogenomics: Prospecting for information in a data-rich landscape
- 655 Richard Fagan & Mark Swindells**
Bioinformatics, target discovery and the pharmaceutical/biotechnology industry
- 662 Alexander Kamb & David H-F Teng**
Transdominant genetics, peptide inhibitors and drug targets
- 670 Thomas A Winters**
Gene targeted agents: New opportunities for rational drug development
- 682 M Stacey Ricci & Wafik S El-Deiry**
Novel strategies for therapeutic design in molecular oncology using gene expression profiles

Indexes

Complete contents, authors and subject indexes to Volume 2 appear at the end of this issue.
